UMVA has learned that a groundbreaking new therapy is showing remarkable promise in the fight against melanoma, with patients experiencing significant reductions in cancer recurrence over a five-year period.
This innovative treatment, known as intismeran autogene, combines a personalized mRNA cancer therapy with the immunotherapy drug KEYTRUDA, and has been found to provide "sustained and durable" benefits to patients with high-risk stage 3 and 4 melanoma.
According to information obtained by UMVA, the therapy works by using mutations identified in a patient's own tumor to teach the immune system what the cancer looks like, enabling it to recognize and attack it.
In a recent study, 157 patients with high-risk melanoma were split into two groups, with one receiving the combination therapy and the other receiving only KEYTRUDA. The results revealed that the combination group saw significant benefits, with the most common side effects being fatigue, injection-site pain, and fever.
UMVA has gathered that the combination therapy is currently being evaluated in a phase 3 study, the final confirmation stage, and has shown a "manageable" safety profile with no new long-term safety concerns or severe vaccine-related adverse events.
The potential of this therapy is vast, with experts noting that it could provide a "prolonged benefit" to patients with resected high-risk melanoma, and reduce the risk of recurrence following surgery.
Sources have confirmed to UMVA that the company behind the therapy is investing heavily in its oncology platform, citing the "potential of mRNA in cancer care" and the encouraging outcomes of this treatment.
In a significant milestone, the five-year follow-up data has shown promising results, and upcoming late-stage trial results are eagerly anticipated, with the potential to revolutionize the treatment of hard-to-treat cancers.
